Loomis Sayles & Co. L P Has $1.03 Billion Holdings in Novo Nordisk A/S (NYSE:NVO)

Loomis Sayles & Co. L P decreased its position in Novo Nordisk A/S (NYSE:NVO) by 3.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,623,915 shares of the company’s stock after selling 273,522 shares during the period. Novo Nordisk A/S makes up 1.3% of Loomis Sayles & Co. L P’s holdings, making the stock its 18th biggest holding. Loomis Sayles & Co. L P owned about 0.19% of Novo Nordisk A/S worth $1,026,849,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. International Assets Investment Management LLC grew its position in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the period. DSM Capital Partners LLC lifted its position in shares of Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after buying an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd bought a new stake in Novo Nordisk A/S during the third quarter worth $98,765,000. Marshall Wace LLP grew its position in Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after buying an additional 689,441 shares during the period. Finally, Sanctuary Advisors LLC bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $41,646,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $105.06 on Monday. The stock has a market cap of $471.46 billion, a price-to-earnings ratio of 34.00, a P/E/G ratio of 1.35 and a beta of 0.42. The stock’s 50-day moving average is $115.48 and its 200 day moving average is $128.81. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.